You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither SPIE nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the SPIE website.
26 February 2013Improved delivery of magnetic nanoparticles with chemotherapy cancer treatment
Most nanoparticle-based cancer therapeutic strategies seek to develop an effective individual cancer cell or metastatic
tumor treatment. Critical to the success of these therapies is to direct as much of the agent as possible to the targeted
tissue while avoiding unacceptable normal tissue complications. In this light, three different cisplatinum/magnetic
nanoparticle (mNP) administration regimens were investigated. The most important finding suggests that clinically
relevant doses of cisplatinum result in a significant increase in the tumor uptake of systemically delivered mNP. This
enhancement of mNP tumor uptake creates the potential for an even greater therapeutic ratio through the addition of
mNP based, intracellular hyperthermia.
The alert did not successfully save. Please try again later.
Alicia A. Petryk, Andrew J. Giustini, Rachel E. Gottesman, P. Jack Hoopes, "Improved delivery of magnetic nanoparticles with chemotherapy cancer treatment," Proc. SPIE 8584, Energy-based Treatment of Tissue and Assessment VII, 85840H (26 February 2013);